Dermorphin is a heptapeptide opioid originally described in the skin secretions of frogs of the genus Phyllomedusa. It is being studied experimentally for its high affinity for μ-opioid receptors, modulation of nociception, and neurophysiological effects.
Concentration (test)
Unspecified
Packaging
Glass vial with sterile closure (5 mg powder)
Storage
2–8 °C, protect from moisture and light
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
dermorphin; μ-opioid heptapeptide
In laboratory studies, Dermorphin is associated with research in areas such as:
- nociception and μ-opioid signaling,
- neural pain pathways and synaptic transmission,
- tolerance, desensitization and receptor internalization,
- neuroendocrine and autonomic reflexes,
- motility and secretion in gastrointestinal models.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is Dermorphin?
Dermorphin is a short peptide from the class of endogenous opioids, described in the skin secretions of some amphibians. It has high affinity for μ-opioid receptors and is used in model systems as a tool to investigate mechanisms of pain processing, synaptic plasticity and autonomic reflexes. The peptide contains a D-amino acid, which may contribute to protease stability and different pharmacokinetics compared to conventional linear peptides.
How Dermorphin works
Upon binding to the μ-opioid receptor (MOR), it activates G i/o proteins, inhibits adenylate cyclase, and reduces intracellular cAMP. Subsequently, K + channels open and Ca 2+ entry is inhibited, leading to neuronal hyperpolarization and decreased release of excitatory neurotransmitters. In experimental models, changes in pain threshold, synaptic plasticity, and regulatory circuits in the CNS and PNS are observed.
Researched effects and interesting facts
-
Strong μ-opioid affinity: used to map receptor-specific responses in models of nociception.
-
Neural excitability: hyperpolarization and inhibition of neurotransmitter release at the presynaptic level.
-
Receptor dynamics: studying desensitization, internalization, and tolerance during prolonged exposure to agonists.
-
Autonomic and gastrointestinal models: monitoring motility and secretion regulated by opioid signaling.
-
Peptide stability: the presence of a D-residue is associated with increased resistance to proteolysis compared to L-sequences.
Dosage in studies
-
Dose: Unspecified (low microgram ranges are often used depending on protocol and target tissue).
-
Form: subcutaneously or intramuscularly after preparation of solution from lyophilized powder.
-
Frequency: Unspecified (determined by design and biomarkers monitored).
-
Duration: Unspecified (short-term and longer experiments depending on the aim of the study).
The information provided is based on research protocols and is for educational purposes only. It is not intended for real-world use outside of a laboratory setting.
Possible side effects (injectable form)
- local irritation, redness or tenderness at the injection site,
- sedation, dizziness, nausea; at higher exposure, risk of respiratory depression typical of opioid agonists,
- changes in GIT motility (constipation) and pruritus.
Resources
- Review papers on μ-opioid receptors and G i/o -mediated signaling (cAMP, K + /Ca 2+ channels).
- Publications describing the isolation of dermorphin from amphibian skin secretions and its pharmacological properties.
- Experimental studies on the antinociceptive effects of peptide MOR agonists and mechanisms of tolerance.
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
